c-Abl Mediates α-Synuclein Toxicity: A Promising Therapeutic Target in Parkinson's Disease and α-Synucleinopathies

被引：0
|
作者：
Brahmachari, S. [1 ,2 ,3 ]
Mao, X. [1 ,2 ,3 ]
Karuppagounder, S. S. [1 ,2 ,3 ]
Lee, Y. [1 ,2 ,3 ]
Dawson, V. L. [1 ,2 ,3 ,4 ,5 ,6 ]
Ko, H. S. [1 ,2 ,7 ]
Dawson, T. M. [1 ,2 ,6 ,7 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD USA
[2] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA
[3] Adrienne Helis Malvin Med Res Fdn, New Orleans, LA USA
[4] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Stem Cell Programs, Baltimore, MD USA
[5] Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA
[6] Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Baltimore, MD USA
[7] Diana Helis Henry Med Res Fdn, New Orleans, LA USA
来源：
CELL TRANSPLANTATION | 2014年 / 23卷 / 06期
关键词：
D O I：
暂无
中图分类号：
Q813 [细胞工程];
学科分类号：
摘要：
引用
收藏
页码：764 / 764
页数：1
相关论文
共 50 条
  • [21] α-Synuclein as a Diagnostic Marker and Therapeutic Target for Parkinson Disease
    Luan Ming-Yue
    Wang Zhao-Xia
    Deng Jian-Wen
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2022, 49 (01) : 86 - 99
  • [22] Mitochondrial homeostasis regulation: A promising therapeutic target for Parkinson's disease
    Yao, Meng-Fan
    Dang, Tao
    Wang, Hua-Jun
    Zhu, Xiao-Zhong
    Qiao, Chen
    BEHAVIOURAL BRAIN RESEARCH, 2024, 459
  • [23] Repurposing of Kinase Inhibitors to Target c-Abl as Potential Therapeutics for Alzheimer's Disease
    Zhu, Qingzhang
    Chen, Jianchun
    Wu, Xi
    Jin, Xiaoping
    Ruan, Bing
    JOURNAL OF PHARMACEUTICAL INNOVATION, 2014, 9 (04) : 331 - 340
  • [24] Repurposing of Kinase Inhibitors to Target c-Abl as Potential Therapeutics for Alzheimer’s Disease
    Qingzhang Zhu
    Jianchun Chen
    Xi Wu
    Xiaoping Jin
    Bing Ruan
    Journal of Pharmaceutical Innovation, 2014, 9 : 331 - 340
  • [25] Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson’s disease
    Chukwunonso K. Nwabufo
    Omozojie P. Aigbogun
    Journal of Neurology, 2022, 269 : 5762 - 5786
  • [26] Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson's disease
    Nwabufo, Chukwunonso K.
    Aigbogun, Omozojie P.
    JOURNAL OF NEUROLOGY, 2022, 269 (11) : 5762 - 5786
  • [27] Alpha-synuclein as a potential biomarker and therapeutic target for parkinson's disease
    Kalia, L.
    JOURNAL OF NEUROCHEMISTRY, 2019, 150 : 35 - 35
  • [28] Development of C-terminal α-Synuclein Vaccine for Treatment and Prevention of Parkinson's Disease and Other Synucleinopathies
    Barbour, R.
    Elmaarouf, A.
    Louie, L.
    Tam, S.
    Tourino, C.
    Campbell, B.
    Kinney, G.
    Zago, W.
    MOVEMENT DISORDERS, 2022, 37 : S469 - S469
  • [29] The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model
    Lee, Saebom
    Kim, Sangjune
    Park, Yong Joo
    Yun, Seung Pil
    Kwon, Seung-Hwan
    Kim, Donghoon
    Kim, Dong Yeon
    Shin, Jae Soo
    Cho, Dae Jin
    Lee, Gong Yeal
    Ju, Hyun Soo
    Yun, Hyo Jung
    Park, Jae Hong
    Kim, Wonjoong Richard
    Jung, Eun Ah
    Lee, Seulki
    Ko, Han Seok
    HUMAN MOLECULAR GENETICS, 2018, 27 (13) : 2344 - 2356
  • [30] The c-Abl/p73 pathway induces neurodegeneration in a Parkinson?s disease model
    Marin, Tamara
    Valls, Cristian
    Jerez, Carolina
    Huerta, Tomas
    Elgueta, Daniela
    Vidal, Rene L.
    Alvarez, Alejandra R.
    Cancino, Gonzalo I.
    IBRO NEUROSCIENCE REPORTS, 2022, 13 : 378 - 387
12345